Dosimetric implications of the potential radionuclidic impurities in 153Sm-DOTMP

• Published in: Applied radiation and isotopes Vol. 185; p. 110246
• Main Authors: Wendt, Richard E., Ketring, Alan R., Frank, R. Keith, Simón, Jaime
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-07-2022
• Subjects: 153Sm-DOTMP; Internal dosimetry; Radionuclidic impurities; Radionuclidic impurities; Internal dosimetry; 153Sm-DOTMP
• ISSN: 0969-8043; 1872-9800
• DOI: 10.1016/j.apradiso.2022.110246

Thehuman internal dosimetry of the radionuclidic impurities of samarium-153 in a new bone-seeking radiopharmaceutical, 153Sm-1,4,7,10tetraazacyclododecanetetramethylenephosponic acid (153Sm-DOTMP), has been estimated from preclinical data. The effective dose from the impurities in lower-specific-activity 153Sm is less than 17% of the effective dose from pure Sm-153. It has a background-equivalent radiation time for a dosage of 37 MBq/kg of less than one-half year.
•The dosimetry of 153Sm-DOTMP using four sources of 153Sm with different amounts of radionuclidic impurities was assessed.•The effective dose from only the impurities in lower-specific-activity 153Sm is less than 17% of that from pure 153Sm.